Business Wire

Lunaphore Announces Formation of New Scientific Advisory Board

Share

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/

Dr. Jerome Galon - Member of Lunaphore Scientific Advisory Board (Photo: Business Wire)

Dr. Jerome Galon - Member of Lunaphore Scientific Advisory Board (Photo: Business Wire)

The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.

The new Lunaphore SAB will be comprised of the following members:

  • Prof. Paolo A. Ascierto, MD

Dr. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC), President of the Fondazione Melanoma Onlus, and of Campania Society of ImmunoTherapy of Cancer (SCITO). He is an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and Associate Editor of Journal of ImmunoTherapy of Cancer. He has been the Principal Investigator in over 100 clinical trials and is the author of more than 450 publications in peer-reviewed journals.

  • Dr. Jérôme Galon

Dr. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. Dr. Galon defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. This scientific contribution was acknowledged by many awards such as the William B. Coley Award, the Award from the National Academy of Science, from the National Academy of Medicine, and European Inventor Award 2019. He is the co-founder of HalioDx and the Chairman of its Scientific Council.

“I am excited to have such great experts in I-O join our SAB,” said Dr. Dupouy, CTO at Lunaphore. “Their expertise in the field will be key to focus our research efforts on the most promising I-O applications, as well as to expand our scientific collaborations worldwide.”

"The key for the immune responsiveness is in the tumor microenvironment,” noted Dr. Ascierto. “Lunaphore has a technology which can potentially make such evaluation easier and greatly contribute to the research field of immunotherapy."

“Lunaphore is developing rapid automated staining instruments based on an innovative microfluidic technology with great potential for multiple research applications,” Dr. Galon said. “I look forward to the next generation hyper-plex immunofluorescence instruments.”

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com.

Contact information

Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Phone: +41 21 353 58 22

Andrea Büchler
Lunaphore Finance and Business Development
Email: andrea.buechler@lunaphore.com
Phone +41 79 598 40 73

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 11:00:00 EETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 09:30:00 EETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 23:58:00 EETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 21:15:00 EETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

Tigo Energy Raises $20 Million in Funding14.1.2021 19:33:00 EETPress release

Tigo Energy, Inc., the worldwide leader in Flex-MLPE (Module Level Power Electronics) today announced a $20 million round of investment, led by Energy Growth Momentum. “2020 has been a breakout year for Tigo and 2021 has the potential for even greater success,” stated Zvi Alon, Chairman and CEO of Tigo. “We are excited to have the EG Momentum team’s support and their working capital will enable us to better serve our current customer base and invest in the future expansion with new customers, new partners and new projects.” The investment will be used to improve upon existing products and develop next generation solutions that maximize returns for PV customers. A portion of the new funds will be used to efficiently and effectively scale. Tigo’s growth has accelerated significantly recently as the company’s products have reached more customer segments and countries throughout the world. With over 40,000 installations in over 100 countries on all 7 continents, Tigo systems generate more

Samsung’s Newest 108Mp Mobile Image Sensor with Advanced Features Captures More Details and Produces Sharper Results14.1.2021 19:00:00 EETPress release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 108-megapixel (Mp) mobile image sensor, Samsung ISOCELL HM3. With a wide spectrum of advanced sensor technologies, the HM3 can capture sharper and more vivid images in ultra-high resolution with faster auto-focus and extended dynamic range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005430/en/ ISOCELL HM3 - 108 megapixel image sensor (Graphic: Business Wire) “While a pixel is just a single dot of color, when in millions, these dots can be transformed into stunning snapshots of life. With more pixels, images are sharper, with fuller details that can maintain their integrity even when enlarged. Samsung has been at the forefront of bringing the most pixels to mobile image sensors as well as various supporting technologies that take sensor performances to the next level,” said Duckhyun Chang, executive vice p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom